Tranzyme Finds Perfect Fit In European Partner For Gastric Motility Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Tranzyme and Norgine will co-develop and co-commercialize ulimorelin, which should begin Phase III trials later this year.
You may also be interested in...
Evolving Standard Of Care May Be To Blame For Phase III Failure Of Ulimorelin, Tranzyme Says
An evolution in the methods hospitals use to speed gastrointestinal recovery after abdominal surgery may have undercut the Phase III efficacy results for the intravenous ghrelin agonist, which was shown to be no better than placebo in the first of two pivotal trials to report.
Evolving Standard Of Care May Be To Blame For Phase III Failure Of Ulimorelin, Tranzyme Says
An evolution in the methods hospitals use to speed gastrointestinal recovery after abdominal surgery may have undercut the Phase III efficacy results for the intravenous ghrelin agonist, which was shown to be no better than placebo in the first of two pivotal trials to report.
BiPar At The Center Of Sanofi's Efforts To Rebuild Its Oncology Business
Phase III PARP inhibitor for triple-negative breast cancer leads Sanofi's efforts to restock its oncology pipeline.